Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog



The Swiss Success Story

16 May 03

Switzerland has been a major force in the development of new medicines for over a century. Around 5% of current global pharmaceutical R&D is attributable to Swiss companies.
Larry Hughes and Dr Faiz Kermani

AXESS welcomes the second edition of “Careers with

13 May 03

Many of our candidates benefited from the previous book, and we are sure that the new edition will build on this success
Ian Thomas

eHealth News Roundup for April 21st – May 2nd 2003

09 May 03

The healthcare industry has utilized the Internet most recently as both a marketing tool and as a facility to pass on important medical information. Leading drug maker Abbott Laboratories will be look
Michael Randle

Behavioral Disorders: ADHD and beyond

09 May 03

Over the past decade, behavioral disorders have received increasing attention, both from the media and medical professionals, however only attention deficit/hyperactivity disorder has emerged as a key
Michael Randle

Introducing EIM: The key to improving pharmaceutic

08 May 03

Enterprise Incentive Management (EIM) software -improves pharmaceutical sales and provides accurate and timely compensation to both direct and indirect sales people. Already used in the pharmaceutica
David Blume

Biotechnology and the Revitalisation of Drug Devel

02 May 03

The development of novel medicines is critical if diseases and disorders are to be effectively treated. As a result, many have looked to biotechnology to provide continuing innovation in the field of
Pietro Bonacossa and Dr Faiz Kermani

Risk and Reward in R&D

02 May 03

Investing in R&D requires long-term planning and the willingness to take risks. Only about 15% of new drugs entering development subsequently reach the market, and the overall expense can be in the or
Faiz Kermaini & Pietro Bonacossa

Asthma Therapeutics: New treatment options and eme

02 May 03

Asthma drives a large but competitive market. Current therapeutics are generally effective but patient compliance is often poor. Future commercial successes in the asthma arena will likely focus on mo
LeadDiscovery/Prof. Peter Barnes

HIV: Justifying premium pricing

01 May 03

Roche's recent announcement of an EU price point of $20,570 per year for its novel HIV fusion inhibitor Fuzeon has brought the issue of pricing HIV therapies to the fore. Roche's premium pricing strat
Michael Randle

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.